Patient-specific antibiotic-resistant bacteria

Patient-specific antibiotic-resistant bacteria refer to unique clinical isolates of pathogenic microorganisms that have developed the ability to survive exposure to antimicrobial drugs designed to kill them (CDC, 2022). These bacteria, often categorized as multidrug-resistant organisms (MDROs), represent a significant clinical challenge because they render standard empirical treatments ineffective, leading to increased morbidity and mortality (WHO, 2023). The resistance mechanisms within these bacteria are diverse, including the production of neutralizing enzymes like carbapenemases, the alteration of molecular targets such as penicillin-binding proteins, and the utilization of efflux pumps to expel toxins (StatPearls, 2023). In the context of drug development and precision medicine, these isolates are the focus of tailored therapeutic strategies, such as bacteriophage therapy or susceptibility-guided antibiotic combinations, which are customized to the genomic and phenotypic profile of the specific strain infecting a patient (NIH, 2019). Because this term describes a broad category of evolving pathogens rather than a single protein or receptor, it is considered a clinical phenotype or a population of organisms rather than a discrete molecular target (PubMed, 2021).

Other names

Multidrug-resistant organismsMDROPatient-specific pathogensClinical bacterial isolatesAntimicrobial-resistant bacteriaDrug-resistant bacteria

Drugs targeting these bacteria typically act by inhibiting cell wall synthesis, disrupting protein synthesis at the ribosomal level, interfering with nucleic acid replication, or damaging the bacterial cell membrane.